Novel Treatment Advances and Approaches in Acute Myeloid Leukemia (AML): Expert Strategies for Improved Clinical and Economic Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2019 to August 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AbbVie, Agios Pharmaceuticals, Celgene, and Jazz Pharmaceuticals

Description:
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for roughly 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages. The five-year survival rate has not improved in older patient’s despite 40 years of research. Fortunately for patients with AML, many new treatments have recently been approved for use. These options, which are among the first new treatments in AML since 1990, have begun to drastically change the treatment paradigm. AML has several subtypes and treatment and prognosis vary among subtypes. After AML has been diagnosed, tests are done to find out the subtype. This is especially important, as several new treatments focus on AML disease with certain mutations. Following older treatment paradigms, AML has been cured in 35–40% of people under 60 years old, but only in 5–15% of people over 60 years old.

Upon completion of this activity, participants will be able to:

  • Quantify the clinical and economic burden of acute myeloid leukemia (AML), including factors that contribute to poor prognosis and increased costs

  • Compare and contrast efficacy and safety profiles of novel therapeutics in AML, including newer targeted, cytotoxic, and antibody-based strategies, in a range of patient populations

  • Distinguish differences in new chemotherapy induction regimens compared to standard formulations

  • Review the impact of intensive treatment initiation for AML in older populations

  • Analyze baseline factors, including age, functional status, antecedent hematologic disorders, therapy-related disease, cytogenetic and mutational findings, among others, that may influence treatment decisions in AML

  • Leverage therapeutic advances and resource utilization data into informed plan decisions and formulary discussions
     

Faculty: Amir T. Fathi, MD
Assistant Professor of Medicine
Massachusetts General Hospital
Harvard School of Medicine

Disclosure:

Dr. Fathi serves as a consultant for Agios, Amphivena, Astellas, Boston Biomedical, Celgene, Daiichi Sankyo, Jazz, and Takeda. He has received grant/research support from Agios, Celgene and Takeda. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
AbbVie, Agios Pharmaceuticals, Celgene, and Jazz Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue